User login
Key clinical point: High mesothelin (MSLN) expression in stage IV colorectal cancer (CRC) was associated with chemoresistant properties and poor prognoses.
Major finding: Patients with high vs low MSLN expression had a low objective response rate (22.0% vs 45.5%; P = .0050), disease control rate (65.9% vs 85.9%; P = .0019), and higher rates of progressive disease (31.0% vs 13.5%; P = .028). The rates of 12-month progression-free survival and 3-year overall survival in high vs low MSNL expression group were 20.0% vs 44.1% (P = .0120) and 23.5% vs 41.5% (P = .0120), respectively.
Study details: Findings are from a retrospective analysis of 254 patients with stage IV CRC who received systemic chemotherapy following primary tumor resection between 2000 and 2019.
Disclosures: The study received no financial or material support. The authors declared no conflict of interests related to this article.
Source: Nagata K et al. Ann Surg Oncol. 2021 Jul 27. doi: 10.1245/s10434-021-10507-y.
Key clinical point: High mesothelin (MSLN) expression in stage IV colorectal cancer (CRC) was associated with chemoresistant properties and poor prognoses.
Major finding: Patients with high vs low MSLN expression had a low objective response rate (22.0% vs 45.5%; P = .0050), disease control rate (65.9% vs 85.9%; P = .0019), and higher rates of progressive disease (31.0% vs 13.5%; P = .028). The rates of 12-month progression-free survival and 3-year overall survival in high vs low MSNL expression group were 20.0% vs 44.1% (P = .0120) and 23.5% vs 41.5% (P = .0120), respectively.
Study details: Findings are from a retrospective analysis of 254 patients with stage IV CRC who received systemic chemotherapy following primary tumor resection between 2000 and 2019.
Disclosures: The study received no financial or material support. The authors declared no conflict of interests related to this article.
Source: Nagata K et al. Ann Surg Oncol. 2021 Jul 27. doi: 10.1245/s10434-021-10507-y.
Key clinical point: High mesothelin (MSLN) expression in stage IV colorectal cancer (CRC) was associated with chemoresistant properties and poor prognoses.
Major finding: Patients with high vs low MSLN expression had a low objective response rate (22.0% vs 45.5%; P = .0050), disease control rate (65.9% vs 85.9%; P = .0019), and higher rates of progressive disease (31.0% vs 13.5%; P = .028). The rates of 12-month progression-free survival and 3-year overall survival in high vs low MSNL expression group were 20.0% vs 44.1% (P = .0120) and 23.5% vs 41.5% (P = .0120), respectively.
Study details: Findings are from a retrospective analysis of 254 patients with stage IV CRC who received systemic chemotherapy following primary tumor resection between 2000 and 2019.
Disclosures: The study received no financial or material support. The authors declared no conflict of interests related to this article.
Source: Nagata K et al. Ann Surg Oncol. 2021 Jul 27. doi: 10.1245/s10434-021-10507-y.